Gossamer Bio, which is developing in-licensed immunotherapies for asthma and other indications, raised $276 million by offering an upsized 17.3 million shares at $16, the indicated IPO price. Insiders indicated an interest in purchasing $100 million (36% of deal size) worth of shares on the IPO. At pricing, Gossamer commands a fully diluted market cap of $1.1 billion. Gossamer Bio plans to list on the Nasdaq under the symbol GOSS. BofA Merrill Lynch, SVB Leerink, Barclays and Evercore ISI acted as lead managers on the deal.
